
    
      In this prospective phase II study, eligible patients are received cisplatin plus paclitaxel
      for 2-4 cycles combined with metformin orally. The investigators aim to compare the tumor
      metabolic pathway and tumor microenvironment of pre-chemotherapy endoscopic biopsy samples
      and post-chemotherapy surgical resection samples.
    
  